GZGuohua Zeng

Guohua Zeng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guohua Zeng has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaolu Duan

    Department of Urology, Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

    4 shared publications
  • Hongxing Liu

    Department of Urology, Guangdong Provincial Key Laboratory of Urological Diseases, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510230, China

    3 shared publications
  • Jiehui Zhong

    Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, 510120, China

    3 shared publications
  • Shujue Li

    Department of Urology, Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

    3 shared publications
  • Wenzhe Chen

    Guangdong Provincial Key Laboratory of Urological Diseases, Guangdong Engineering Research Center of Urinary Minimally invasive surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, 510120, P. R. China

    3 shared publications
  • Xinyuan Sun

    Department of Urology, Guangzhou Institute of Urology, Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

    3 shared publications

Latest Publications

  • Open Access

    Bio-hybrid nanovesicles with multimodal antioxidant and immunomodulatory functions attenuate acute kidney injury

    by Wenzhe Chen, Haitao Yuan, Haitao Liu, Min Zou, Junhui Chen, Yanting Liang, Xiaoxian Wang, Jingbo Ma, Mengyun Hou, Jinyue He, et al.

    Oxidative stress, marked by a disparity between the generation of reactive oxygen species (ROS) and the body's antioxidant defenses, is crucial in the development of acute kidney injury (AKI), where excessive ROS accumulation drives tubular epithelial cell damage and inflammatory cascades. Dysregulated inflammatory immunity further exacerbates tissue injury, highlighting the need for integrated strategies that simultaneously regulate oxidative defense and inflammatory immune activation. Given this rationale, we developed bio-hybrid nanovesicles (ES-EVs) by integrating ES NPs of epigallocatechin-3-gallate (EGCG) and selenomethionine (SeMet) into extracellular vesicles derived from human umbilical cord mesenchymal stem cells (hUMSC-EVs). In this study, ES NPs were synthesized, preserving the biological activities of EGCG and SeMet while enhancing their stability and bioavailability. Furthermore, the integration of the potent antioxidant and anti-inflammatory properties of ES NPs with the passive targeted delivery and immunomodulatory functions of hUMSC-EVs offers a promising strategy for the treatment of AKI. In vitro evaluation confirmed that ES-EVs were able to mitigate oxidative stress, protect mitochondria, inhibit apoptosis and polarize macrophages toward an anti-inflammatory phenotype, thereby preventing excessive inflammatory cascades. In vivo experiments demonstrated that ES-EVs effectively enhanced renal function, repaired damaged renal tissue and decreased apoptosis. ES-EVs aid renal function recovery by inhibiting oxidative stress, maintaining inflammatory homeostasis and reprogramming the immune microenvironment. RNA sequencing analysis demonstrated that ES-EVs can alleviate cisplatin induced oxidative stress and DNA damage, and at the same time play an anti-inflammatory role. In summary, this study has established a bionic hybrid nanovesicular with multifunctional therapeutic properties, which lays the foundation for the clinical translation of management of AKI.


  • Impact of thyroid diseases on urinary stone composition: a decade-Long analysis based on propensity score matching

    by Mengting Wang, Kemin Liu, Qianjun Li, Kunzhi Luo, Weizhi Zheng, Yiping Lai, Haojie Wu, Ying Liang, Baoqing Sun, Guohua Zeng, et al.

  • TE-RPA: One-tube telomerase extension recombinase polymerase amplification-based electrochemical biosensor for precise diagnosis of urothelial carcinoma

    by Mengting Wang, Wenzhe Chen, Mingzhao Li, Fuyang Lin, Jiehui Zhong, Wenrui Ouyang, Chao Cai, Guohua Zeng, Hongxing Liu


  • Open Access

    Navigating the Evolving Landscape of Primary Hyperoxaluria: Traditional Management Defied by the Rise of Novel Molecular Drugs

    by Yueqi Huang, Wei Zhu, Jia Zhou, Qiulin Huang, Guohua Zeng

    Primary hyperoxalurias (PHs) are inherited metabolic disorders marked by enzymatic cascade disruption, leading to excessive oxalate production that is subsequently excreted in the urine. Calcium oxalate deposition in the renal tubules and interstitium triggers renal injury, precipitating systemic oxalate build-up and subsequent secondary organ impairment. Recent explorations of novel therapeutic strategies have challenged and necessitated the reassessment of established management frameworks. The execution of diverse clinical trials across various medication classes has provided new insights and knowledge. With the evolution of PH treatments reaching a new milestone, prompt and accurate diagnosis is increasingly critical. Developing early, effective management and treatment plans is essential to improve the long-term quality of life for PH patients.


  • Open Access

    Cerium oxide-based nanozyme suppresses kidney calcium oxalate crystal depositions via reversing hyperoxaluria-induced oxidative stress damage

    by Jiwang Deng, Bangxian Yu, Zhenglin Chang, Sicheng Wu, Guanlin Li, Wenzhe Chen, Shujue Li, Xiaolu Duan, Wenqi Wu, Xinyuan Sun, et al.

    Oxidative stress damage to renal epithelial cells is the main pathological factor of calcium oxalate calculi formation. The development of medicine that could alleviate oxidative damage has become the key to the prevention and treatment of urolithiasis. Herein, porous nanorods CeO2 nanoparticles (CNPs) were selected from CeO2 with different morphologies as an antioxidant reagent to suppress kidney calcium oxalate crystal depositions with excellent oxidation resistance due to its larger specific surface area. The reversible transformation from Ce3+ to Ce4+ could catalyze the decomposition of excess free radicals and act as a biological antioxidant enzyme basing on its strong ability to scavenge free radicals. The protection capability of CNPS against oxalate-induced damage and the effect of CNPS on calcium oxalate crystallization were studied. CNPS could effectively reduce reactive oxygen species production, restore mitochondrial membrane potential polarity, recover cell cycle progression, reduce cell death, and inhibit the formation of calcium oxalate crystals on the cell surface in vitro. The results of high-throughput sequencing of mRNA showed that CNPs could protect renal epithelial cells from oxidative stress damage caused by high oxalate by suppressing the expression gene of cell surface adhesion proteins. In addition, CNPS can significantly reduce the pathological damage of renal tubules and inhibit the deposition of calcium oxalate crystals in rat kidneys while having no significant side effect on other organs and physiological indicators in vivo. Our results provide a new strategy for CNPS as a potential for clinical prevention of crystalline kidney injury and crystal deposition.


  • Accurate diagnosis of prostate cancer with CRISPR-based nucleic acid test strip by simultaneously identifying PCA3 and KLK3 genes

    by Wenzhe Chen, Sicheng Wu, Guanlin Li, Xiaolu Duan, Xinyuan Sun, Shujue Li, Yan Zhao, Di Gu, Guohua Zeng, Hongxing Liu


  • Open Access

    The antibiotic strategies during percutaneous nephrolithotomy in China revealed the gap between the reality and the urological guidelines

    by Shike Zhang, Gonghui Li, Ludong Qiao, Dehui Lai, Zhican He, Lingyue An, Peng Xu, Hans-Göran Tiselius, Guohua Zeng, Junhua Zheng, et al.

    Background: Correct perioperative antibiotic strategies are crucial to prevent postoperative infections during percutaneous nephrolithotomy (PCNL). We aimed to compare the realistic antibiotic strategies applied in China with current urological guidelines. Methods: Between April and May 2020, urologists from China were invited to finish an online cross-sectional survey. The questionnaire was designed according to the current urological guidelines and literatures. Results: 3393 completed responses were received. 61.1% (2073/3393) respondents had urological experience of more than 10 years. 72.4% urologists chose multiple-dose antibiotics for patients with both negative urine culture (UC-) and negative urine microscopy (UM-) preoperatively. Respondents in central China (OR = 1.518; 95% CI 1.102–2.092; P = 0.011), east China (OR = 1.528; 95% CI 1.179–1.979; P = 0.001) and northeast China (OR = 1.904; 95% CI 1.298–2.792; P = 0.001) were more likely to prescribe multiple-dose antibiotic for UC-UM- patients. Notably, the respondents who finished PCNL exceeded 100 cases per year were in favor of single-dose administration (OR = 0.674; 95% CI 0.519–0.875; P = 0.003). There are only 8.3% urologists chose single-dose antibiotic for UC-UM+ patients, whereas 65.5% administered antibiotics for 1–3 days. Meanwhile, for UC+ patients, 59.0% of the urologists applied antibiotics shorter than 1 week, and only 26.3% of the urologists carried out routine re-examination of UC. Moreover, postoperative antibiotics were frequently prescribed for 3–6 days (1815; 53.5%). Finally, although 88.2% urologists considered stone culture important for management of postoperative antibiotics as the guideline recommended, only 18.5% performed it routinely. Conclusions: The antibiotic strategies are different between current practice in China and the urological guidelines. The dissimilarities suggested that further studies should be conducted to investigate the reasons of the differences and standardize the application of antibiotics.


  • The association between dairy products consumption and prostate cancer risk: a systematic review and meta-analysis

    by Zifan Zhao, Donghong Wu, Sirui Gao, Dongda Zhou, Xiaoying Zeng, Yuxuan Yao, Yilin Xu, Guohua Zeng

    In this study, we conducted a meta-analysis to estimate the relationship between the consumption of dairy products and the risk of prostate cancer. We searched PubMed, Embase and Cochrane databases for relevant articles and identified a total of thirty-three cohort studies between 1989 and 2020. The qualities of included studies were assessed using Newcastle–Ottawa scale. Pooled adjusted relative risks (RR) with 95 % CI were calculated. We performed subgroup analyses stratified by dairy type, prostate cancer type, follow-up years, treatment era, collection times, adjustment for confounders and geographic location. In the subgroup analysis stratified by prostate cancer type, the pooled RR were 0·98 (95 % CI 0·94, 1·03) in the advanced group, 1·10 (95 % CI 0·98, 1·24) in the non-advanced group and 0·92 (95 % CI 0·84, 1·00) in the fatal group. In the dose–response analysis, a positive association for the risk of prostate cancer was observed for total dairy products 400 g/d (RR: 1·02; 95 % CI 1·00, 1·03), total milk 200 g/d (RR: 1·02; 95 % CI 1·01, 1·03), cheese 40 g/d (RR: 1·01; 95 % CI 1·00, 1·03) and butter 50 g/d (RR: 1·03; 95 % CI 1·01, 1·05). A decreased risk was observed for the intake of whole milk 100 g/d (RR: 0·97; 95 % CI 0·96, 0·99). Our meta-analysis suggests that high intakes of dairy products may be associated with an increased risk of prostate cancer; however, since many of the studies were affected by prostate-specific antigen (PSA) screening bias, additional studies with an adjustment of PSA screening are needed.


  • Open Access

    Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy

    by Zezhen Liu, Jiehui Zhong, Jie Zeng, Xiaolu Duan, Jianming Lu, Xinyuan Sun, Qinwei Liu, Yingke Liang, Zhuoyuan Lin, Weide Zhong, et al.

    The aim of this study was to elucidate the correlation between m6A modification and the tumor immune microenvironment (TIME) in prostate cancer (PCa) and to identify the m6A regulation patterns suitable for immune checkpoint inhibitors (ICIs) therapy. We evaluated the m6A regulation patterns of PCa based on 24 m6A regulators and correlated these modification patterns with TIME characteristics. Three distinct m6A regulation patterns were determined in PCa. The m6A regulators cluster with the best prognosis had significantly increased METTL14 and ZC3H13 expression and was characterized by low mutation rate, tumor heterogeneity, and neoantigens. The m6A regulators cluster with a poor prognosis had markedly high KIAA1429 and HNRNPA2B1 expression and was characterized by high intratumor heterogeneity and Th2 cell infiltration, while low Th17 cell infiltration and Macrophages M1/M2. The m6Ascore was constructed to quantify the m6A modification pattern of individual PCa patients based on m6A-associated genes. We found that the low-m6Ascore group with poor prognosis had a higher immunotherapeutic response rate than the high-m6Ascore group. The low-m6Ascore group was more likely to benefit from ICIs therapy. This study was determined that immunotherapy is more effective in low-m6Ascore PCa patients with poor prognosis.


  • Open Access

    Landscape of microenvironment in Randall’s plaque by single-cell sequencing

    by Zezhen Liu, Xiaolu Duan, Xinyuan Sun, Jiehui Zhong, Wen Zhong, Bangxian Yu, Zhijian Zhao, Zanlin Mai, Hongxing Liu, Shujue Li, et al.

    Randall’s plaque is significantly associated with the occurrence of nephrolithiasis. However, the microenvironment of Randall’s plaque is poorly characterized. To investigate the microenvironment of Randall’s plaque, we analyzed single-cell RNA data of 3 Randall’s plaque and 3 normal renal papillae tissue and identified 11 different cell types. We screened differentially expressed genes among all cell types between Randall’s plaque and normal renal papillae. The microenvironment showed two cell types with multiple stone formation-associated transcriptomic programs. Contrary to previous studies, we did not observe macrophage M1/M2 imbalance. Notably, we detected ossification-associated macrophage is enriched in Randall’s plaque and validated GPNMB and ACP5 were potential biomarkers on the ossification-associated macrophage. We also identified an endothelial subset harboring active communication (COL15A1+ PCDH17+ endothelial, DPECs) with other cells. Together with Immunofluorescence, we validated ossification-associated macrophage and DPECs are enriched in Randall’s plaque tissue. Finally, cell-to-cell communication revealed that Loop of Henle, DPECs, and osteoblasts-associated macrophages was the main source of SPP1 signaling. Our work will further the understanding of the microenvironment among Randall’s plaque tissues and provide deep insight into immune modulation.